Effects of clinically relevant radionuclides on the activation of a type I interferon response by radiopharmaceuticals in syngeneic murine tumor models
Kerr, C. P.; Sheehan-Klenk, J.; Grudzinski, J. J.; Adam, D. P.; Nguyen, T. P. T.; de Aguiar Ferreira, C.; Bates, A. M.; Jin, W. J.; Kwon, O.; Olson, A. P.; Lin, W.; Hyun, M.; Jagodinsky, J. C.; Powers, M.; Sriramaneni, R. N.; Clark, P. A.; Shea, A. G.; Comas Rojas, H.; Choi, C.; Massey, C. F.; Zangl, L. M.; Pinchuk, A. N.; Aluicio-Sarduy, E.; Kim, K.; Engle, J. W.; Hernandez, R.; Bednarz, B. P.; Weichert, J. P.; Morris, Z. S.
Show abstract
Radiopharmaceutical therapies (RPT) activate a type I interferon (IFN1) response in tumor cells. We hypothesized that the timing and amplitude of this response varies by isotope. We compared equal doses delivered by 90Y, 177Lu, and 225Ac in vitro as unbound radionuclides and in vivo when chelated to NM600, a tumor-selective alkylphosphocholine. Response in murine MOC2 head and neck carcinoma and B78 melanoma was evaluated by qPCR and flow cytometry. Therapeutic response to 225Ac-NM600+anti-CTLA4+anti-PD-L1 immune checkpoint inhibition (ICI) was evaluated in wild-type and stimulator of interferon genes knockout (STING KO) B78. The timing and magnitude of IFN1 response correlated with radionuclide half-life and linear energy transfer. CD8+/Treg ratios increased in tumors 7 days after 90Y- and 177Lu-NM600 and day 21 after 225Ac-NM600. 225Ac-NM600+ICI improved survival in mice with WT but not with STING KO tumors, relative to monotherapies. Immunomodulatory effects of RPT vary with radioisotope and promote STING-dependent enhanced response to ICIs in murine models. TeaserThis study describes the time course and nature of tumor immunomodulation by radiopharmaceuticals with differing physical properties.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer 96%
- FLASH Bragg-peak irradiation with a therapeutic carbon ion beam: first in vivo results 96%
- Improving SBRT by re-wiring immunosuppressive neutrophils in murine pancreatic ductal adenocarcinoma 96%
Similar papers in this journal
- Immune stromal components impede biological effectiveness of carbon ion therapy in a preclinical model of pancreatic ductal adenocarcinoma 98%
- PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity 97%
- Sensitization to Ionizing Radiation by MEK inhibition is Dependent on SNAI2 in Fusion-negative Rhabdomyosarcoma 93%
Similar papers in this journal
- Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models 95%
- MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma 95%
- Tumor-localized interleukin-2 and interleukin-12 combine with radiation therapy to safely potentiate regression of advanced malignant melanoma in pet dogs 93%
Similar papers in this journal
- Priming versus propagating: distinct immune effects of an alpha- versus beta-particle emitting radiopharmaceutical when combined with immune checkpoint inhibition 98%
- Integration of machine learning and genome-scale metabolic modeling identifies multi-omics biomarkers for radiation resistance 95%
- Hemoxygenase-1 as a key mediator of acute radiation pneumonitis revealed in a human lung alveolus-on-a-chip 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.